Renca-Luc

Renca-Luc is a bioluminescent derivative of the murine Renca renal carcinoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental Renca cell line was spontaneously derived from a renal cell carcinoma in a BALB/c mouse and is one of the most widely used syngeneic models for renal cell carcinoma (RCC) in immuno-oncology research. Renca tumors grow aggressively and are poorly immunogenic in BALB/c hosts, making this model valuable for evaluating immunotherapy approaches including checkpoint inhibitors, cytokine therapies, and cancer vaccines in an immunocompetent setting that recapitulates the immunosuppressive microenvironment characteristic of human RCC.

The stable luciferase integration in Renca-Luc enables sensitive, noninvasive bioluminescence imaging (BLI) of tumor burden in orthotopic subrenal capsule and subcutaneous xenograft models in syngeneic BALB/c mice. Following luciferin administration, the emitted signal correlates with viable tumor cell number, supporting longitudinal monitoring of tumor engraftment, growth kinetics, and therapeutic response without repeated invasive procedures. Renca-Luc is widely used for in vivo evaluation of anti-RCC agents, combination immunotherapy strategies, and angiogenesis inhibitors in preclinical renal cancer research.

Renca-Luc retains the established biological and immunological properties of the parental Renca line, including BALB/c syngeneic compatibility and its characteristic poorly immunogenic phenotype. The luciferase modification substantially enhances experimental sensitivity and enables real-time pharmacodynamic assessment of treatment efficacy. Researchers should verify luciferase activity, growth kinetics, and immunological characteristics under their specific experimental conditions prior to large-scale in vivo use.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

7. Follow the procedure described under Post-Thaw Recovery

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.